800 watts @ 4 ohms or 500 watts @ 8 ohms Discreet FET preamp Push activated Gain A/B and limiter defeat 10dB pad Four band active EQ w/variable contour Effects loop & tuner mute XLR out, pre/post EQ Defeatable limiter Two speakon outputs Headphone/line output 10.75×8.5×1.75 4.9 lbs.
In addition, activated HSCs gain contractile phenotype and increasing evidence suggests that the contractile force generated by HSCs contributes to the regulation of sinusoidal blood flow and the development of portal hypertension [3].
In addition to causing developmental defects, activating or gain-of-function mutations in FGFRs are found sporadically in a number of different types of cancer.
After exposure to each of 8 different ligands that activate TLRs 2, 3, 4, 5, 7, 8, and 9, CD8+ T cells are activated and gain expression of the C type lectin CD69 that may promote their retention in lymphoid tissues.
The catalytic subunit consists of four isoforms: p110α, β, γ and δ. 3 In many human cancers, the PI3K pathway is frequently activated through gain of function mutations in the PIK3CA gene that encodes p110α.
This proves that fusions of MSI+ cells with APC can functionally present FSPs to T cells which in turn can be activated and gain the potential to attack MSI+ tumor cells.
So, how do you activate Score Gains Thinking?
Increasing evidence also suggests that activated HSCs gains contractile function, which contributes to the intrahepatic hemodynamic changes in cirrhosis [19].
RPN4 has also been shown to be activated by gain-of-function alleles of PDR1 [ 12] and the RPN4 promoter contains a PDRE which is actually bound by Pdr1p in vivo and in vitro [ 2, 29].
This work has integrated microarray-based global gene expression and epigenomic profiling of prostate cancer cells and their normal counterparts and found that transcriptional activating marks (gain of H3K4me3 or loss of H3K27me3) and silencing marks (gain of H3K27me3 or loss of H3K4me3) were tightly associated with upregulated and downregulated genes in prostate cancer cells, respectively.
In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the epidermal growth factor receptor (EGFR).
